InflaRx (NASDAQ:IFRX) Shares Sold by Eversept Partners LP

Eversept Partners LP trimmed its holdings in InflaRx (NASDAQ:IFRX - Free Report) by 69.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 492,452 shares of the company's stock after selling 1,129,335 shares during the period. Eversept Partners LP owned about 0.84% of InflaRx worth $1,216,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Raymond James Financial Inc. acquired a new stake in InflaRx in the fourth quarter valued at $1,576,000. Walleye Capital LLC bought a new stake in shares of InflaRx in the 4th quarter worth about $51,000. Commonwealth Equity Services LLC raised its stake in shares of InflaRx by 20.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company's stock valued at $275,000 after purchasing an additional 19,000 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of InflaRx by 32.8% during the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock worth $119,000 after purchasing an additional 11,900 shares during the last quarter. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IFRX has been the topic of several research reports. HC Wainwright restated a "buy" rating and set a $8.00 price objective on shares of InflaRx in a research note on Friday, March 21st. Guggenheim increased their target price on shares of InflaRx from $7.00 to $10.00 and gave the stock a "buy" rating in a report on Wednesday, March 26th.

InflaRx Stock Down 1.5 %

Shares of NASDAQ:IFRX traded down $0.02 during trading on Friday, hitting $1.30. 86,652 shares of the company traded hands, compared to its average volume of 226,009. The business's fifty day moving average is $1.22 and its 200-day moving average is $1.82. The stock has a market capitalization of $87.27 million, a price-to-earnings ratio of -1.20 and a beta of 2.21. InflaRx has a one year low of $0.82 and a one year high of $2.82.

InflaRx (NASDAQ:IFRX - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.18. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%. On average, analysts forecast that InflaRx will post -1.04 EPS for the current year.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.